A5081447772- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Advanced Breast Cancer Therapies
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- Phagocytosis and Immune Regulation
- Microtubule and mitosis dynamics
- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Lung Cancer Treatments and Mutations
- Endoplasmic Reticulum Stress and Disease
- Cytokine Signaling Pathways and Interactions
- Advanced Biosensing Techniques and Applications
- Cancer Treatment and Pharmacology
- Melanoma and MAPK Pathways
- Chronic Lymphocytic Leukemia Research
- Click Chemistry and Applications
- Cell Adhesion Molecules Research
- Radiomics and Machine Learning in Medical Imaging
- Cancer Research and Treatments
- Virus-based gene therapy research
- Biosimilars and Bioanalytical Methods
- Multiple Myeloma Research and Treatments
- Radiopharmaceutical Chemistry and Applications
- Cancer-related Molecular Pathways
Seagen (Canada)
2024
Seagen (United States)
2018-2023
Oregon Department of Education
2018
Willamette University
2018
University of Tennessee at Knoxville
2002
Abstract Brentuximab vedotin, a CD30-directed antibody–drug conjugate (ADC), is approved for clinical use in multiple CD30-expressing lymphomas. The cytotoxic payload component of brentuximab vedotin monomethyl auristatin E (MMAE), highly potent microtubule-disrupting agent. Preclinical results provided here demonstrate that treatment cancer cells with or free MMAE leads to catastrophic disruption the microtubule network eliciting robust endoplasmic reticulum (ER) stress response culminates...
SGN-CD228A is an investigational antibody-drug conjugate (ADC) directed to melanotransferrin (CD228, MELTF, MFI2, p97), a cell-surface protein first identified in melanoma. consists of humanized antibody, hL49, with high specificity and affinity for CD228 that stably conjugated 8 molecules the clinically validated microtubule-disrupting agent monomethyl auristatin E (MMAE) via novel glucuronide linker. We performed comprehensive IHC studies, which corroborated published RNA sequencing data...
The oncogenic receptor HER2 is overexpressed in many cancers, including up to 20% of breast cancers. Despite the availability HER2-targeted treatments, patients’ disease often progresses during therapy, underscoring need for novel treatment strategies. addition tucatinib, a reversible, highly selective tyrosine kinase inhibitor (TKI), with trastuzumab and capecitabine significantly improved survival outcomes patients HER2-positive metastatic cancer, those active brain metastases. We...
<h3>Background</h3> Tisotumab vedotin (TV) is an investigational antibody-drug conjugate composed of a tissue factor (TF)-directed human monoclonal antibody covalently linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via protease-cleavable linker. TV demonstrated single activity (24% objective response rate [ORR]) in previously treated recurrent or metastatic cervical cancer (NCT03438396) where currently, there no standard care and ORRs are typically less than 15%...
Abstract Background: Tucatinib is an orally administered, reversible HER2-targeted small molecule tyrosine kinase inhibitor that potently and selectively inhibits HER2 relative to the closely related EGFR. In a phase Ib clinical trial in HER2+ metastatic breast cancer, tucatinib combination with antibody-drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1) was well tolerated demonstrated activity pretreated patients HER2-positive cancer (Borges VF et al., 2018). Here, we present...
Abstract Background: Tucatinib is an orally administered, reversible, highly specific HER2 tyrosine kinase inhibitor recently approved by the FDA in combination with trastuzumab and capecitabine for adult patients advanced unresectable or metastatic HER2-positive breast cancer (mBC), including brain metastases, that have failed at least one anti-HER2 regimen setting. In a phase IB clinical trial, tucatinib HER2-targeted antibody-drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1) was well...
<h3>Background</h3> TIGIT is an immunoregulatory receptor expressed on activated and memory T cells, regulatory cells (Tregs), NK cells. binding to CD155 CD112 tumor drives inhibitory signal resulting in decreased cell functionality. targeting has been reported release these signals, drive Treg depletion, augment CD8 generation, promote anti-tumor responses. <h3>Methods</h3> To evaluate the impact of antibody backbone anti-TIGIT action three distinct antibodies with differential effector...
Abstract Disitamab vedotin (DV, RC48-ADC) is an antibody-drug conjugate (ADC) that targets cancers expressing HER2, oncogenic growth factor receptor promotes cell proliferation and survival. DV consists of a novel anti-HER2 monoclonal antibody, disitamab, conjugated with the microtubule-disrupting agent monomethyl auristatin E (MMAE) via cleavable linker. has multimodal antitumor mechanisms action include direct cytotoxicity HER2-expressing cancer cells bystander effect based-cytotoxicity...
<p>Supplementary Figure S6. Brentuximab vedotin’s multifaceted mechanism of action</p>
<p>Supplementary Table S1. List of antibodies</p>
<p>Supplementary Table S1. List of antibodies</p>
<p>Supplementary Figure S4. pIRE, pJNK, and CHOP upregulation in lymphoma lines treated with brentuximab vedotin or MMAE</p>
<p>Supplementary Figure S6. Brentuximab vedotin’s multifaceted mechanism of action</p>
<p>Supplementary Figure S5. Brentuximab vedotin enhances cytotoxic T-cell infiltration into LCL tumors</p>
<p>Supplementary Figure S4. pIRE, pJNK, and CHOP upregulation in lymphoma lines treated with brentuximab vedotin or MMAE</p>
<div>Abstract<p>Brentuximab vedotin, a CD30-directed antibody–drug conjugate (ADC), is approved for clinical use in multiple CD30-expressing lymphomas. The cytotoxic payload component of brentuximab vedotin monomethyl auristatin E (MMAE), highly potent microtubule-disrupting agent. Preclinical results provided here demonstrate that treatment cancer cells with or free MMAE leads to catastrophic disruption the microtubule network eliciting robust endoplasmic reticulum (ER) stress...
<p>Supplementary Figure S2. ICD hallmarks observed from tumor cell lines treated with brentuximab vedotin or MMAE</p>
<p>Supplementary Figure S2. ICD hallmarks observed from tumor cell lines treated with brentuximab vedotin or MMAE</p>
<p>Supplementary Figure S3. Raw pixel intensities for western blots in 2</p>
<p>Supplementary figures and table</p>
<p>Supplementary Figure S3. Raw pixel intensities for western blots in 2</p>
<p>Supplementary Figure S1. Overview of ICD</p>
<p>Supplementary Figure S5. Brentuximab vedotin enhances cytotoxic T-cell infiltration into LCL tumors</p>
<div>Abstract<p>Brentuximab vedotin, a CD30-directed antibody–drug conjugate (ADC), is approved for clinical use in multiple CD30-expressing lymphomas. The cytotoxic payload component of brentuximab vedotin monomethyl auristatin E (MMAE), highly potent microtubule-disrupting agent. Preclinical results provided here demonstrate that treatment cancer cells with or free MMAE leads to catastrophic disruption the microtubule network eliciting robust endoplasmic reticulum (ER) stress...
<p>Supplementary figures and table</p>